Safety Findings Support Use of Peri-Transplant Ruxolitinib in Myelofibrosis
Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
The pilot study aimed to assess the safety and efficacy of the per-transplant ruxolitinib strategy. In terms of safe, Ali says that strategy was well-tolerated, with most of the toxicities being grade 1 in severity. Few patients experienced grade 2 or 3 toxicities, which included renal failure and cardiac arrest in 2 patients. These events were not related to ruxolitinib, Ali explains.
Results also showed that the incidence of high-grade graft-versus-host disease was low in this study. These findings confirm the original hypothesis of the study.
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More
